证券代码：600833 证券简称：第一医药 公告编号：临 2025-022 1 上海第一医药股份有限公司 关于参与设立基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 一、基金情况概述 上海第一医药股份有限公司（以下简称 "公司"）参与投资设立上海创特私募投 资基金合伙企业（有限合伙）（以下简称"基金"），具体详见公司于 2025 年 4 月 9 日披露的《上海第一医药股份有限公司关于参与设立基金暨关联交易的公告》（公告 编号：临 2025-016）。 此前，基金已完成工商注册登记，并完成基金首期实缴 1000 万元，具体详见公司 于 2025 年 4 月 26 日披露的《上海第一医药股份有限公司关于参与设立基金的进展公 告》（公告编号：临 2025-017）。 2025 年 5 月 13 日，基金已在中国证券投资基金业协会完成备案手续，具体详见 公司于 2025 年 5 月 15 日披露的《上海第一医药股份有限公司关于参与设立基金备案 完成的公告》（公告编号：临 2025-021）。 二、基金进展情况 截至目 ...

沪指5月26日下跌0.05%，申万所属行业中，今日上涨的有22个，涨幅居前的行业为传媒、计算机，涨 幅分别为2.14%、1.39%。跌幅居前的行业为汽车、医药生物，跌幅分别为1.78%、1.08%。医药生物行 业位居今日跌幅榜第二。 资金面上看，两市主力资金全天净流出88.30亿元，今日有10个行业主力资金净流入，传媒行业主力资 金净流入规模居首，该行业今日上涨2.14%，全天净流入资金11.64亿元，其次是轻工制造行业，日涨幅 为1.04%，净流入资金为6.00亿元。 主力资金净流出的行业有21个，汽车行业主力资金净流出规模居首，全天净流出资金30.76亿元，其次 是医药生物行业，净流出资金为25.75亿元，净流出资金较多的还有非银金融、电力设备、食品饮料等 行业。 医药生物行业资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 600276 | 恒瑞医药 | -2.11 | 0.83 | -18461.84 | | 603259 | 药明康德 | -0.61 | 1.18 | -173 ...

Market Overview - The Shanghai Composite Index is at 3389.00 points, above the six-month moving average, with a slight increase of 0.04% [1] - The total trading volume of A-shares today is 512.26 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 75 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Meirui New Materials (300848) with a deviation rate of 8.28% and a price increase of 8.72% [1] - Wankong Intelligent Manufacturing (603070) with a deviation rate of 7.52% and a price increase of 9.97% [1] - Hitec High-tech (002023) with a deviation rate of 5.81% and a price increase of 10.01% [1] Detailed Stock Performance - The following stocks have notable performance metrics: - Sichuan Jiuzhou (000801) with a price increase of 3.47% and a deviation rate of 2.56% [2] - Phoenix Light (600071) with a price increase of 3.05% and a deviation rate of 2.47% [2] - Raytheon Micro Power (301050) with a price increase of 4.04% and a deviation rate of 2.26% [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has released its annual top ten investor protection cases, highlighting various legal actions and mechanisms aimed at safeguarding investor rights in the capital market [1][2]. Group 1: Investor Protection Cases - The top ten cases include significant legal actions such as representative lawsuits and mediation of securities fraud, market manipulation, and private fund disputes [1]. - Notable cases include the first-ever representative lawsuits for market manipulation and the first case of public nomination of independent directors by an investor protection agency [1][9]. Group 2: Specific Cases - The representative lawsuits for Jin Tong Ling and Mei Shang Ecological involve collective actions against financial fraud, with both companies accused of inflating profits and failing to disclose related party transactions [2][3]. - The Jin Tong Ling case involves approximately 50,000 investors, while the Mei Shang Ecological case involves over 33,000 investors [3]. Group 3: Regulatory Actions - The CSRC has taken strict actions against fraudulent issuance and market manipulation, with a notable case involving Evergrande Group, which faced a fine of 4.175 billion yuan for fraudulent bond issuance [4][5]. - The case against Wang, who manipulated the market using 145 accounts, resulted in a civil lawsuit with a total penalty of 5.7 billion yuan [5][6]. Group 4: Innovative Mediation Mechanisms - The "Tai An Tui" case marked the first successful zero-cost representative lawsuit through judicial collaboration, recovering 572 million yuan for investors [7]. - The introduction of a "demonstration mediation + arbitration confirmation" mechanism has successfully resolved private fund disputes, with 97 investors receiving nearly 300 million yuan in compensation [8][9]. Group 5: Independent Director Nomination - The first public nomination of an independent director by an investor protection agency occurred in the case of First Medical, which is seen as a significant step towards improving the independent director selection mechanism [9].

Core Viewpoint - The successful nomination of independent director Du Jian by the China Securities Investor Services Center marks a significant step in the reform of the independent director system in China, following the first case with First Pharmaceutical in June 2024, indicating a trend towards improved corporate governance in listed companies [1][4]. Group 1: Nomination Process - The nomination of Du Jian was conducted in collaboration with institutional investors, adhering to market-oriented and legal principles, and received support from 8 shareholders, representing approximately 1.2288% of the total voting rights of Shangfeng Cement [2]. - The voting results showed that the shares in favor of the nomination exceeded the required threshold, indicating that the center could potentially nominate candidates independently in the future [2][3]. Group 2: Impact on Corporate Governance - The initiative by the China Securities Investor Services Center to publicly nominate independent directors has garnered widespread attention and is seen as a positive exploration for enhancing internal governance of listed companies [4]. - The involvement of the center allows for a more rigorous selection of independent directors based on their past performance and ability to protect minority shareholders' rights, thereby improving the overall governance of listed companies [4][5]. - The successful implementation of this nomination process is expected to encourage more investors to exercise their shareholder rights, thereby enhancing the supervisory and balancing forces within corporate governance structures [5].

Core Viewpoint - The article highlights the ongoing efforts by the China Securities Regulatory Commission (CSRC) to enhance investor protection through stricter regulations and innovative measures aimed at addressing capital market irregularities and safeguarding investor rights [1][2][3]. Regulatory Actions - In 2024, the CSRC investigated 739 cases of securities and futures violations, resulting in 592 penalties, a 10% increase year-on-year. The number of responsible parties penalized rose by 24% to 1,327, and 118 individuals were banned from the market, up 15% [1]. - The CSRC has implemented measures to address the long-standing issue of major shareholders misappropriating company funds, with companies facing delisting risks if they fail to return misappropriated funds in a timely manner [1][5]. Investor Protection Initiatives - The introduction of the special representative litigation system has been expanded, with successful applications in the Jin Tong Ling and Mei Shang Ecology cases in 2024, aimed at efficiently resolving collective disputes [6]. - The Investor Protection Center (IPC) has publicly nominated independent directors for listed companies, with the first successful case being First Pharmaceutical, where 99.99% of voting shares supported the nomination [3][4]. Legal Developments - The IPC's lawsuit against Tai'an Tui for the recovery of misappropriated funds resulted in a full recovery of 572 million yuan through a judicial mediation process, marking a significant achievement in shareholder litigation [4][5]. - The IPC's efforts led to the successful recovery of 5.34 billion yuan in misappropriated funds from *ST Xintong, which faced delisting risks due to non-compliance with fund recovery mandates [5]. Anti-Fraud Measures - A new anti-fraud mechanism has been established in collaboration with local police to combat investment-related scams, resulting in the prevention of 732 fraud cases and the recovery of 19.265 million yuan [7][8].

Group 1 - Vanke A received a loan of 1.552 billion yuan from its largest shareholder, Shenzhen Metro Group, to repay the principal and interest of publicly issued bonds, with a loan term of 36 months and an annual interest rate of 2.34%, lower than the 1-year LPR [2] - Chengfei Integration announced that its stock has been on a six-day trading limit, confirming that there are no undisclosed significant matters affecting the company [3] - Dongpeng Beverage's shareholder, Kunpeng Investment, reduced its shareholding from 6.44% to 5.43%, a decrease of 1.01 percentage points, through trading activities [4] Group 2 - Baofeng Energy plans to repurchase shares worth between 1 billion and 2 billion yuan, with a maximum repurchase price of 22.80 yuan per share [7] - Huakayi Yibai announced that shareholders plan to reduce their holdings by up to 3% of the company's total shares [6] - China Pacific Insurance reported a 10.4% year-on-year increase in original insurance premium income for its life insurance subsidiary, totaling 115.359 billion yuan [22]

Group 1 - Vanke A's largest shareholder, Shenzhen Metro Group, plans to provide a loan of up to 1.55 billion yuan to repay the company's bonds [1] - Yidelong reported a net profit of 41.77 million yuan for Q1 2025, a year-on-year increase of 34.19% [1] - Overseas Chinese Town A achieved a contract sales amount of 1.78 billion yuan in April, a year-on-year increase of 10% [1][2] Group 2 - Dajin Heavy Industry's subsidiary signed a contract worth approximately 1 billion yuan for an offshore wind power project with a European energy company [4] - Liao Port Co. announced the resignation of Chairman Wang Zhixian due to reaching retirement age [4] - China Energy Construction's application for a specific stock issuance has been approved by the Shanghai Stock Exchange [6] Group 3 - Xinhua Insurance reported a 27% year-on-year increase in premium income from January to April, totaling 85.38 billion yuan [11] - 吉祥航空's passenger turnover increased by 6.34% in April, with a seat occupancy rate of 86.16% [13] - New City Holdings reported a contract sales amount of approximately 1.76 billion yuan in April, a year-on-year decrease of 52.46% [28] Group 4 - Three Yuan Bio announced a preliminary ruling of a 3.49% countervailing duty on its products in the U.S. [23] - Shanghai Pharmaceutical's product, Wengjing Decoction Granules, has been approved for production [20] - A strategic cooperation agreement was signed between *ST Dali and Zhuhai Yunzhou Intelligent Technology Co., Ltd. to promote the development of intelligent unmanned equipment [22] Group 5 - The construction of the automotive lightweight forging precision processing project by Sanlian Forging has been completed [25] - The company Tianma Technology reported an output of approximately 1,480.16 tons of eel in April [18][19] - The company Victory Technology plans to invest up to 3 billion yuan for share repurchase [42]

证券代码：600833 证券简称：第一医药 公告编号：临 2025-021 上海第一医药股份有限公司 托管人名称：华夏银行股份有限公司 2025 年 4 月 26 日，公司披露《关于参与设立基金的进展公告》（公告编号：临 2025-017），基金首期实缴已完成。 2025 年 5 月 13 日，基金已在中国证券投资基金业协会完成备案手续，并取得《私 募投资基金备案证明》，主要内容如下： 基金名称：上海创特私募投资基金合伙企业（有限合伙） 备案编码：SAXM42 管理人名称：上海商投创业投资有限公司 关于参与设立基金备案完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 上海第一医药股份有限公司（以下简称 "公司"）参与投资设立上海创特私募投 资基金合伙企业（有限合伙）（以下简称"基金"），具体详见公司于 2025 年 4 月 9 日披露的《上海第一医药股份有限公司关于参与设立基金暨关联交易的公告》（公告 编号：临 2025-016）。 备案日期：2025 年 5 月 13 日 公司将持续关注基金的后续进展情况，并按照 ...

金十数据5月14日讯，第一医药公告，公司参与投资设立的上海创特私募投资基金合伙企业（有限合 伙）已于2025年5月13日在中国证券投资基金业协会完成备案手续，并取得《私募投资基金备案证 明》，备案编码为SAXM42。基金管理人为上海商投创业投资有限公司，托管人为华夏银行股份有限公 司。公司将持续关注基金的后续进展情况，并及时履行信息披露义务。 第一医药：基金已完成备案 ...